Abstract—Due to the tumor heterogeneity and the diversity of the immune microenvironment, not all HCC patients could achieve the desired therapeutic effect from the immunotherapy. We identified three immune clusters with increasing ESTIMATE scores and redefined them as Cluster A (high immune), B (intermediate immune), and C (low immune) in HCC. Through the combination of the bulk and single-cell RNA-seq data, statistical differencesofinfiltrating immune cells, tumor mutational burden, and immune checkpoints were comprehensively exploredto compare thediversity of immune microenvironment among clusters. Additionally, we constructed an immune risk model and validated its prognosis value for the survival prediction in HCC. This study identifies the specific subtypes through the tumor immune microenvironment and reflects the distinct tumor phenotype and detailed immune landscape in HCC. And it would provide new insights into immunotherapy and improve the clinical benefit for HCC treatment.